Abstract:Recent data suggested that cancer appears to be a process that is fuelled both by genetic alterations and by epigenetic mechanisms. Epigenetics refer to the study of changes in gene expression that can be mitotically inherited, but is not associated with the changes in the coding sequence of the affected genes. DNA methylation, the best understood mechanism in epigenetics, is an enzyme-mediated chemical modification that adds methyl (CH3) groups at selected sites on DNA. In humans and most mammals, DNA methylation only affects the cytosine base (C), when it is followed by a guanosine (G). DNA methylation in the promoter regions is a powerful mechanism for the suppression of gene activity. It was thought formerly that two pathways by which tumor suppressor genes became disabled were intragenic mutations and loss of chromosomal material [(loss of heterozygosity (LOH) or homozygous deletion)]. More recent studies have firmly established methylation as one potential hit and represent a third mechanism by which tumor suppressor genes are inactivated, and that, in some cases, methylation is the sole mechanism responsible for the inactivation of a tumor suppressor gene. There is clearly a tumor-specific methylation pattern in many types of tumor. An individual tumor within a single patient may have characteristic set of gene with an increased propensity to become methylated as compared with a tumor of the same type in a different patient. Methylation changes appear to precede apparent malignancy in many cases. Therefore, methylation can distinguish tumor types and subtypes, and should be useful in improving early detection of potentially cancerous cells. Methylation markers may also be used to predict response to chemotherapy or duration of patient survival. The efficacy of hypomethylating agents (e.g. 5-aza-2'-deoxycytidine) as antineoplastic agents has been attributed to two distinct mechanism: cytotoxicity and induction of hypomethylation. Some clinical trials with them have been performed in solid tumors and malignant hematologic disease. In general, the response rates were not satisfactory. A variety of methods are used to evaluate the methylation status of genes. MSP (methylation-specific PCR) is very sensitive and has been widely used. It takes advantage of the DNA sequence difference existing between methylated and unmethylated DNA after bisulfite treatment.

Advances in Targeted Induction of DNA Methylation and Cancer Therapy

Research Progress on DNA Demethylation in Anti-Tumor Therapy

Technologies for Targeting DNA Methylation Modifications: Basic Mechanism and Potential Application in Cancer.

DNA Hypermethylation As a Chemotherapy Target.

Recent progress in DNA methyltransferase inhibitors as anticancer agents

Targeting DNA methyltransferases for cancer therapy

DNA Methylation: From Cancer Biology to Clinical Perspectives

DNA methylation and cancer: transcriptional regulation, prognostic, and therapeutic perspective

Regulation of DNA methylation machinery by epi-miRNAs in human cancer: emerging new targets in cancer therapy

DNA Methylation and Histone Deacetylation: Interplay and Combined Therapy in Cancer

DNA Methylation Profiles in Cancer Diagnosis and Therapeutics

Circulating Methylated DNA As Biomarkers for Cancer Detection

DNA Methyltransferases: Emerging Targets for the Discovery of Inhibitors As Potent Anticancer Drugs

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application

The Roles of DNA Methylation in Human Neoplasms

Methylomics and cancer: the current state of methylation profiling and marker development for clinical care

DNA Methylation and the Regulation of Tumor

Epigenetic Regulation in Cancer Therapy: from Mechanisms to Clinical Advances

More Questions Than Answers about the Potential Anticancer Agents: Dna Methylation Inhibitors